Physician profile
Janice E Vaughn
NPI 1316247596
$6,906.72
in general payments reported to CMS, 2019-2025
22 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,463 · 2022: $1,129 · 2023: $1,248 · 2024: $1,540 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $27.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.13 |
| Education | $27.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.33 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,350.79 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $888.03 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $632.37 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $479.20 | 2021-2023 | Trintellix |
| Alkermes, INC. | $453.03 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $370.89 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $217.51 | 2021 | |
| Ironshore Pharmaceuticals INC. | $178.96 | 2021-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $130.62 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $105.46 | 2023 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $92.52 | 2025 | |
| Lilly USA, LLC | $64.25 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $62.79 | 2024 | Fanapt |
| Gilead Sciences, INC. | $21.45 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $20.89 | 2025 | Sublocade |
| Braeburn INC. | $18.50 | 2024 | Brixadi |
| Jazz Pharmaceuticals INC. | $17.85 | 2022 | |
| Exact Sciences Corporation | $15.81 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2024 | |
| Astellas Pharma US INC | $13.16 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $13.03 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.